Cybin News

Cybin's CYB003 Shows Promise in MDD Treatment, Justifying Buy Rating

TipRanksMar 14 07:18 ET

Buy Rating Affirmed for Cybin on Promising CYB003 Clinical Data and Strategic FDA Designations

TipRanksMar 13 11:35 ET

Cybin Analyst Ratings

BenzingaMar 13 11:30 ET

Cybin (CYBN) Gets a Buy From Oppenheimer

TipRanksFeb 20 07:57 ET

Cybin Analyst Ratings

BenzingaFeb 15 12:39 ET

Promising Futures for Cybin's Psychedelic Treatments: A Buy Rating Analysis

TipRanksFeb 15 11:55 ET

Oppenheimer Sticks to Their Buy Rating for Cybin (CYBN)

TipRanksJan 9 07:54 ET

Buy Rating Affirmed for Cybin Based on Advancements in Psychedelic Treatments and Optimistic Valuation

TipRanksJan 4 11:05 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Cybin (CYBN), Nevro Corp (NVRO) and Biogen (BIIB)

TipRanksDec 1, 2023 08:02 ET

Analysts Conflicted on These Healthcare Names: Protara Therapeutics (TARA), Cybin (CYBN) and Roche Holding AG (OtherRHHVF)

TipRanksDec 1, 2023 06:40 ET

Analysts Offer Insights on Healthcare Companies: Cybin (CYBN), ADMA Biologics (ADMA) and Halozyme (HALO)

TipRanksNov 17, 2023 06:20 ET

Cybin Analyst Ratings

BenzingaNov 17, 2023 06:13 ET

Compelling Factors Bolster Buy Rating for Cybin Inc.: Emphasis on Promising Phase 2 Trial Results and Strategic Acquisitions

TipRanksNov 2, 2023 14:11 ET

Promising Phase 2 Results and Financial Projections Bolster Buy Rating for Cybin: An Analysis by Patrick Trucchio

TipRanksOct 31, 2023 09:26 ET

HC Wainwright & Co. Reiterates Buy on Cybin, Maintains $10 Price Target

BenzingaOct 31, 2023 09:22 ET

Cybin Analyst Ratings

BenzingaOct 31, 2023 09:21 ET

Cybin's Promising Developments and Emerging Data: A Comprehensive Analysis Justifying Buy Rating and $10 Price Target

TipRanksOct 2, 2023 11:46 ET

What 11 Analyst Ratings Have To Say About Cybin

BenzingaSep 1, 2023 12:00 ET

Canaccord Genuity Reiterates Buy on Cybin, Maintains $5 Price Target

BenzingaSep 1, 2023 10:33 ET

Cybin Analyst Ratings

BenzingaSep 1, 2023 10:32 ET